Literature DB >> 18511207

Inhibition of spinal cytosolic phospholipase A(2) expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia.

D H Kim1, B Fitzsimmons, M P Hefferan, C I Svensson, E Wancewicz, B P Monia, G Hung, M Butler, M Marsala, X-Y Hua, T L Yaksh.   

Abstract

Activation of the spinal phospholipase A(2) (PLA(2)) -cyclooxygenase (COX) -prostaglandin signaling pathway is widely implicated in nociceptive processing. Although the role of spinal COX isoforms in pain signal transmission has been extensively characterized, our knowledge of PLA(2) enzymes in this cascade is limited. Among all PLA(2) groups, cytosolic calcium-dependent PLA(2) group IVA (cPLA(2)IVA) appears to be the predominant PLA(2) enzyme in the spinal cord. In the present study we sought to (i) characterize anatomical and cellular distribution and localization of cPLA(2)IVA in dorsal horn of rat spinal cord, (ii) verify efficacy and selectivity of intrathecal (IT) delivery of an antisense oligonucleotide (AS) targeting rat cPLA(2)IVA mRNA on spinal expression of this enzyme, and (iii) examine the effect of down-regulation of spinal cPLA(2)IVA on peripheral tissue injury-induced pain behavior. Here we demonstrate that cPLA(2)IVA is constitutively expressed in rat spinal cord, predominantly in dorsal horn neurons and oligodendrocytes but not in astrocytes or microglia. Intrathecal injection of AS significantly down-regulated both protein and gene expression of cPLA(2)IVA in rat spinal cord, while control missense oligonucleotide (MS) had no effect. Immunocytochemistry confirmed that the reduction occurred in neurons and oligodendrocytes. cPLA(2)IVA AS did not alter expression of several other PLA(2) isoforms, such as secretory PLA(2) (groups IIA and V) and calcium-independent PLA(2) (group VI), indicating that the AS was specific for cPLA(2)IVA. This selective knockdown of spinal cPLA(2)IVA did not change acute nociception (i.e. paw withdrawal thresholds to acute thermal stimuli and intradermal formalin-induced first phase flinching), however, it significantly attenuated formalin-induced hyperalgesia (i.e. second phase flinching behavior), which reflects spinal sensitization. Thus the present findings suggest that cPLA(2)IVA may specifically participate in spinal nociceptive processing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511207      PMCID: PMC2640426          DOI: 10.1016/j.neuroscience.2008.04.033

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  55 in total

1.  Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat.

Authors:  A B Malmberg; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

Review 2.  Therapeutic applications of oligonucleotides.

Authors:  S T Crooke
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

3.  Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction.

Authors:  T Yamamoto; T L Yaksh
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

4.  A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7.

Authors:  J Y Channon; C C Leslie
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

Review 5.  Antisense oligonucleotide strategies in neuropharmacology.

Authors:  C Wahlestedt
Journal:  Trends Pharmacol Sci       Date:  1994-02       Impact factor: 14.819

6.  Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin.

Authors:  Anthony H Dickenson; Ann F Sullivan
Journal:  Pain       Date:  1987-09       Impact factor: 6.961

7.  Potentiation of NMDA receptor currents by arachidonic acid.

Authors:  B Miller; M Sarantis; S F Traynelis; D Attwell
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

8.  Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats.

Authors:  A B Malmberg; T L Yaksh
Journal:  J Neurosci       Date:  1995-04       Impact factor: 6.167

Review 9.  Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters.

Authors:  L Urban; S W Thompson; A Dray
Journal:  Trends Neurosci       Date:  1994-10       Impact factor: 13.837

10.  Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen.

Authors:  S Glover; M S de Carvalho; T Bayburt; M Jonas; E Chi; C C Leslie; M H Gelb
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

View more
  9 in total

1.  Inhibition of cPLA2 activation by Ginkgo biloba extract protects spinal cord neurons from glutamate excitotoxicity and oxidative stress-induced cell death.

Authors:  Zhen Zhao; Naikui Liu; Jingya Huang; Pei-Hua Lu; Xiao-Ming Xu
Journal:  J Neurochem       Date:  2011-01-19       Impact factor: 5.372

2.  Selective activation of microglia facilitates synaptic strength.

Authors:  Anna K Clark; Doris Gruber-Schoffnegger; Ruth Drdla-Schutting; Katharina J Gerhold; Marzia Malcangio; Jürgen Sandkühler
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

3.  Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function.

Authors:  Hiroyasu Sato; Yuki Isogai; Seiko Masuda; Yoshitaka Taketomi; Yoshimi Miki; Daisuke Kamei; Shuntaro Hara; Tetsuyuki Kobayashi; Yukio Ishikawa; Toshiharu Ishii; Kazutaka Ikeda; Ryo Taguchi; Yoshikazu Ishimoto; Noriko Suzuki; Yasunori Yokota; Kohji Hanasaki; Toshiko Suzuki-Yamamoto; Kei Yamamoto; Makoto Murakami
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

Review 4.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Expression genetics identifies spinal mechanisms supporting formalin late phase behaviors.

Authors:  Xiangqi Li; Peyman Sahbaie; Ming Zheng; Jennifer Ritchie; Gary Peltz; Jeffrey S Mogil; J David Clark
Journal:  Mol Pain       Date:  2010-02-11       Impact factor: 3.395

Review 6.  Phospholipases A2 and inflammatory responses in the central nervous system.

Authors:  Grace Y Sun; Phullara B Shelat; Michael B Jensen; Yan He; Albert Y Sun; Agnes Simonyi
Journal:  Neuromolecular Med       Date:  2009-10-24       Impact factor: 3.843

Review 7.  The search for novel analgesics: targets and mechanisms.

Authors:  Tony L Yaksh; Sarah A Woller; Roshni Ramachandran; Linda S Sorkin
Journal:  F1000Prime Rep       Date:  2015-05-26

8.  Epidural dexamethasone decreased inflammatory hyperalgesia and spinal cPLA₂ expression in a rat formalin test.

Authors:  Sam-Hong Min; Jung-Sub Soh; Ji-Yong Park; Sung-Uk Choi; Hye-Won Lee; Jae-Jin Lee; Jae-Hwan Kim
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

Review 9.  Secreted Phospholipases A₂ from Animal Venoms in Pain and Analgesia.

Authors:  Vanessa O Zambelli; Gisele Picolo; Carlos A H Fernandes; Marcos R M Fontes; Yara Cury
Journal:  Toxins (Basel)       Date:  2017-12-19       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.